Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations by Fang, Shenying et al.
Effects of MDM2, MDM4 and TP53 Codon 72
Polymorphisms on Cancer Risk in a Cohort Study of
Carriers of TP53 Germline Mutations
Shenying Fang
1, Ralf Krahe
2, Guillermina Lozano
2, Younghun Han
1, Wei Chen
1, Sean M. Post
2, Baili
Zhang
2, Charmaine D. Wilson
2, Linda L. Bachinski
2, Louise C. Strong
2., Christopher I. Amos
1*
.
1Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America, 2Department of Genetics, University of Texas
M.D. Anderson Cancer Center, Houston, Texas, United States of America
Abstract
Background: Previous studies have shown that MDM2 SNP309 and p53 codon 72 have modifier effects on germline P53
mutations, but those studies relied on case-only studies with small sample sizes. The impact of MDM4 polymorphism on
tumor onset in germline mutation carriers has not previously been studied.
Methodology/Principal Findings: We analyzed 213 p53 germline mutation carriers including 168(78.9%) affected with
cancer and 174 who had genotypic data. We analyzed time to first cancer using Kaplan-Meier and Cox proportional hazards
methods, comparing risks according to polymorphism genotypes. For MDM2 SNP309, a significant difference of 9.0 years in
the average age of cancer diagnosis was observed between GG/GT and TT carriers (18.6 versus 27.6 years, P=0.0087). The
hazards ratio was 1.58 (P=0.03) comparing risks among individuals with GG/GT to risk among TT, but this effect was only
significant in females (HR=1.60, P=0.02). Compared to other genotypes, P53 codon 72 PP homozygotes had a 2.24 times
(P=0.03) higher rate for time to develop cancer. We observed a multiplicative joint effect of MDM2 and p53 codon72
polymorphism on risk. The MDM4 polymorphism had no significant effects.
Conclusions/Significance: Our results suggest that the MDM2 SNP309 G allele is associated with cancer risk in p53 germline
mutation carriers and accelerates time to cancer onset with a pronounced effect in females. A multiplicative joint effect
exists between the MDM2 SNP309 G allele and the p53 codon 72 G allele in the risk of cancer development. Our results
further define cancer risk in carriers of germline p53 mutations.
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Introduction
p53 functions as a transcription factor and tumor suppressor,
responding to cellular stresses such as DNA damage and
oncogene activation. It modulates the transcription of genes that
regulate cell cycle arrest, apoptosis, and senescence [1].
Aberrant function of p53 proteins is a frequent mechanism by
which its inhibitory role in tumorigenesis is weakened, both in
sporadic cancers, which often develop mutations of p53,a n di n
individuals who inherit germline mutations. Mutations of p53
account for the majority of families with Li-Fraumeni syndrome
(LFS), an uncommon autosomal dominant cancer syndrome
[2,3]. Individuals with LFS are at an increased risk for a wide
spectrum of neoplasms including breast, lung, brain, and
adrenocortical cancers, and leukemias and sarcomas [4–6].
Unlike the dominant effect of germline p53 mutation on cancer
risk, germline p53 polymorphisms exert more subtle effects on
tumor onset or risk of cancer by modifying the function of p53.
In particular, the codon 72 R/P polymorphism affects binding
of p53 to p73 and has been associated with altered risk for many
different cancers [7–9].
MDM2 SNP309 (rs2279744; T/G) is located 309 base pairs
downstream from intron 1 in the promoter of MDM2. The single
nucleotide polymorphism (SNP) 309 T.G change has been found
to enhance the affinity of the transcriptional activator Sp1, leading
to increased levels of MDM2, and thereby weakening the p53
pathway of tumor suppression [10]. In germline p53 mutation
carriers, SNP309 was reported to accelerate tumor onset and to be
associated with the development of multiple primary tumors
throughout the lifetime [10–12]}. The presence of the G allele was
found to be highly related to earlier cancer diagnosis in LFS or Li-
Fraumeni2like syndrome. The numbers of affected carriers of a
germline p53 mutation in three earlier published studies were
small and analyses were restricted to include only individuals who
had already developed cancer. Therefore, prior studies have
limited generalizability for individuals at risk for cancer develop-
ment due to inherited p53 mutations who may not yet have
developed cancer.
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with MDM2 to inhibit p53 activity in cellular response to DNA
damage. The human MDM4 gene has been mapped to
chromosome 1q32, a target for amplification in malignant gliomas
[13]. While MDM4 inhibits p53 activity in early embryogenesis in
animal models, MDM4 has a weak effect on p53 activity in many
cell types [14]. Atwal et al(2009) reported that genetic variants in
MDM4 led to an increased risk of early onset of human breast and
ovarian cancers in unrelated individuals [15]. In another
independent case-control study, a polymorphic variant in human
MDM4 was only found to be associated with an accelerated age of
onset of estrogen receptor negative breast cancer [16]. The impact
of MDM4 on age of tumor onset in germline mutation carriers has
not previously been investigated.
In this study, we investigated whether MDM2 SNP309, MDM4,
and p53 codon 72 polymorphisms have any effect on risk for any
type of cancer in carriers of a p53 germline mutation. This is a
long-term systematic follow-up study in which germline p53
mutations and genetic polymorphisms were identified without
respect to the cancer status in the family. This follow-up study with
a larger sample size allowed us to characterize the cancer risks
among carriers of germline p53 mutations. We estimated hazard
ratios by Kaplan-Meier methods and Cox regression to adjust for
covariates and familial correlations by performing the robust
sandwich estimate of Lin and Wei [17].
Materials and Methods
Study Population
The protocol and consent form is annually reviewed by the IRB
at the University of Texas MD Anderson Cancer Center. No
patient names are revealed in any reports or publications from this
study. The present study population consisted of several cohorts of
families that were identified through probands with early onset
sarcoma or multiple cancers and that were found to carry p53
germline mutations. One cohort comprises 107 kindreds identified
through probands with soft-tissue sarcoma (STS) diagnosed before
age 16 years during the years from 1944 to 1975 at The University
of Texas M. D. Anderson Cancer Center (MDACC) who survived
at least 3 years after diagnosis and had samples available for testing
[2,18,19]. We identified 63 individuals in seven STS kindreds as
carriers of a p53 germline mutation. Another cohort included 71
families identified through probands who were diagnosed with
osteosarcoma (OST) before age 20 years during the period from
1944 to 1982 atMDACC who had samplesavailablefortesting. We
identified11 individuals in six OST kindreds who were carriers of a
p53 germline mutation. We also identified 2 carriers from two
kindreds of probands with multiple primary malignant tumors and
p53 germline mutations. The remaining 137 carriers were identified
from 59 LFS kindreds. Subjects were treated as a carrier of a p53
germline mutation if they were shown by genetic testing to carry the
mutation or if both a parent and offspring were demonstrated to
carry the mutation, and thus positive mutation status could be
inferred. We analyzed 213 carriers of a germline p53 mutation in
this study. Of the 213 individuals who could be inferred to have a
p53 mutation, samples were available for 132 individuals, but
MDM4 genotypes were missing for two of these individuals. A
detailed description of the p53 sequencing and genotyping
procedures is provided in the supplemental materials(Text S1;
Figure S1, Figure S2 and Figure S3; Table S1 and Table S2).
Statistical Analysis
We first tested for differences in age at cancer diagnosis among
the different genotype groups using a nonparametric Kruskal-
Wallis test. Among the carriers of a germline p53 mutation, we first
performed a log-rank test for risk differences based on sex and
mutation type, using the Kaplan-Meier product-limit method.
Missing genotype data (n=43, 44, and 42 for MDM2, MDM4, and
p53 codon 72, respectively) were imputed using Linkage software
[20], and estimating population allele frequencies within each
ethnicity. For this analysis, we estimated the likelihood of each
genotype for individuals who had a p53 mutation and at least one
relative who had been genotyped for a MDM2, MDM4,o rp53
codon 72 polymorphism. The probability of a particular genotype
was derived as the ratio of the likelihood for the family given that
the mutation carrier had each particular genotype divided by the
likelihood for the family. Genetic effects of MDM2, MDM4, and
p53 codon 72 polymorphisms were estimated by using a weighted
Cox proportional hazard model, unadjusted or adjusted for sex,
race, and birth year and weighted by the probability of each
genotype (for the inferred data). We took into account the familial
correlation in the model by calculating the robust variance. The
time to onset was from birth to first cancer diagnosis, for those who
had cancer, and the censoring time was from birth to last contact
(fixed to December 31, 2001), death, or study termination, for
those who had no cancer. All statistical analyses were conducted
by using SAS 9.1 (SAS Institute, Cary, NC). A P-value,0.05 was
considered statistically significant.
Results
Of the 213 carriers with a p53 germline mutation analyzed, 168
(78.9%) were affected with cancer, and the mean period from birth
to cancer diagnosis or censoring was 27.9 years (SD=18.2).
Figure 1 illustrates the distribution of cancer occurrences by age
and sex. Female mutation carriers were at higher risk than male
carriers (log-rank test, P=0.0057); the mean age of cancer
diagnosis was 24 years in females and 26 years in males. No risk
difference was detected between the two types of germline
Figure 1. Kaplan-Meier estimated cumulative incidence for
cancer in carriers of a p53 germline mutation by sex.
Observations included 101 males and 112 females (log-rank test
P=0.0057).
doi:10.1371/journal.pone.0010813.g001
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(Figure 2). Stratification analysis showed that the codon 72
polymorphisms in cis had no effect on age of tumor onset in
carriers of dysfunctional missense mutations (P=0.20) or truncat-
ing mutations (P=0.78), and similarly in trans there was no
significant effect when stratified by p53 mutation type. Because
there were missing genotypes for some carriers and a compara-
tively small sample of individual genotypes, hazard ratios (Table
S3) estimated via the proportional Cox model restricted to only the
raw genotype data have limited power. Table S4 shows that allelic
distribution varied significantly among the different ethnicities for
each polymorphism. The best genetic model for each SNP was
determined by choosing the model with the lowest Akaike
information criterion (AIC) value from among the general,
dominant, recessive, and additive models (Table S5).
Comparing the age at diagnosis among those affected with
cancer (table 1), a significant average difference of 9.0 years was
observed for the carriers of a G allele for the MDM2 SNP309
polymorphism compared to TT carriers (18.6 versus 27.6 years,
P=0.0087). When analyzing time to onset including affected and
unaffected individuals who were genotyped we did not observe a
significant difference among genotypes for the MDM2 SNP309
(P=0.5557) (Figure S4). Stratification analysis showed that G
allele carriers had a worse survival than TT homozygotes among
females(Log-Rank test P=0.1483, Wilcoxon test P=0.0950)
(Figure S5), but those two genotype groups among males had
the same survival distributions over time (P.0.1 for both Log-
Rank test and Wilcoxon test)(Figure S6). When including the
imputed data, a trend towards significance was noted for the
univariable analysis of the MDM2 G allele (P=0.0764 unadjusted
and P=0.1067 adjusted analysis) (Table 2), but carriers of a G
allele had a 1.58 fold increased risk for cancer after adjusting for
sex, race, birth year, and effects from other polymorphisms in
multivariable analysis (P=0.0313) (Table 3). Including an
interaction term between MDM2 SNP309 polymorphism and
sex revealed that the G allele was a risk allele among females
(P=0.02) but not among males (P=0.1936). To limit possible
effects of referral bias, further multivariable analysis was
performed among carriers of a p53 germline mutation after
excluding the probands and yielded similar results. Carriers of the
MDM2 G allele had a high risk among all relatives (P=0.0117) or
female relatives (P=0.0089), but no significant effect was noted
among male relatives (P=0.1315) (Table S6).
For MDM4, we identified no significant difference in the
average ages of first cancer diagnosis between AA, AG, and GG
groups (P=0.9680) (Table 1). The log-rank test result shows no
difference in risk of cancer among these three genotypes
(P=0.6646) or between the AG/GG and AA groups
(P=0.3770) (Figure S7). The MDM4 polymorphism did not have
a significant effect on risk of developing cancer because it was not
significant in unadjusted (P=0.1054) or adjusted univariable
analysis (P=0.1584) (Table 2) or multivariable analysis
(P=0.0712) of raw plus inferred genotype data (Table 3). No
significant difference was found for MDM4 polymorphism when
probands were excluded from the analysis (P=0.0752) (Table S6).
While no significant effects were observed in this study, studies in a
larger collection of families are needed to resolve whether MDM4
has any effect on risk for cancer among carriers of a p53 mutation.
For the p53 codon 72 polymorphism, only seven mutation
carriers had the PP genotype. A difference of 4.9 years in mean
age at cancer diagnosis was detected between PP and RP/RR
groups, but the difference was not significant in univariate analyses
(18.5 years versus 23.4, P=0.5828) (Table 1). There was no
significant difference in survival curves among PP, PR, and RR
groups (P=0.0955) when the joint distributions of time to
diagnosis among all genotypes were contrasted, but the time to
diagnosis differed significantly between PP and either PR or RR
genotypes (P=0.0447) according to the log-rank test on genotyped
data (Figure S8). In the full sample, including inferred data, the
codon 72 P allele was a risk allele for cancer in the unadjusted
univariable analysis (P=0.0052), adjusted univariable analysis
(P=0.0327) (Table 2), and multivariable analysis after adjusting
for covariates and other SNPs (HR=2.24, P=0.0287) (Table 3).
Further analysis showed that the PP genotype had a significant
recessive effect on cancer development among males (P,0.0001),
but not among females (P=0.4864). The hazard ratios increased
Figure 2. Kaplan-Meier estimated cumulative incidence for any
cancer in carriers of a p53 germline mutation by mutation type.
Among these 213 carriers(one missing type of mutation), 130 carried a
missense mutation and 82 a truncation mutation (deletion 1, nonsense
50, frame-shift 16, splice 15). Log-rank test P=0.0900.
doi:10.1371/journal.pone.0010813.g002
Table 1. Mean age of tumor diagnosis in affected carriers of a
p53 germline mutation by p53 polymorphism.
Polymorphism Subcategory N (%)
Mean age,
years (SD) P-value*
MDM2 SNP309 GG 15(14.7) 23.5(16.9) 0.0119
GT 38(37.3) 16.7(13.9)
TT 49(48.0) 27.6(18.1)
GG+GT 53(52.0) 18.6(14.9) 0.0087
MDM4 AA 16(16.0) 22.2(16.6) 0.9680
AG 38(38.0) 21.7(15.3)
GG 46(46.0) 23.2(18.7)
p53 codon 72 PP 7(6.9) 18.5(11.2) 0.3463
RP 47(46.1) 25.0(16.6)
RR 48(47.0) 21.8(18.0)
RP+RR 95(93.1) 23.4(17.3) 0.5828
*Kruskal-Wallis test.
doi:10.1371/journal.pone.0010813.t001
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probands (P,0.0001), and the P-value was significant among both
males (P,0.0001) and females (P,0.0001) (Table S6).
Because both MDM2 SNP309 and p53 codon 72 polymorphism
can attenuate the inhibitory role of p53 in tumorigenesis [21], we
examined the joint effect of MDM2 and p53 codon72 polymor-
phism (Table 4). Compared with the reference group carrying no
risk genotype at either locus (i.e., MDM2 TT and p53 codon 72
PR/RR), those with a risk genotype on one of the loci, MDM2
(MDM2 GG/GT and p53 codon 72 PR/RR) were 1.54 times
more likely to have cancer (P=0.0319), and the highest hazard
ratio of 3.25 was observed for those carriers with risk genotypes at
both loci (P=0.0367); this hazard ratio is close to the product of
hazard ratios for the main effects of risk genotype at each locus
(1.5462.36=3.63), suggesting that the two SNPs together have a
multiplicative joint effect.
It is noteworthy that carrier birth year was a significant
covariate in both univariable (Table 2) and multivariable analysis
(Table 3). In carriers of a p53 germline mutation, each subsequent
date of birth increased the cancer risk by 3% (P,0.0001). This
trend was observed for both men and women (Table 3). The
findings suggest genetic anticipation in later birth cohorts or effects
from unmeasured environmental factors that have an increasing
effect on risk over time.
Table 3. Multivariable analysis of hazard ratios for MDM2, MDM4, and p53 codon 72 polymorphisms on age of tumor diagnosis
among carriers of a p53 germline mutation.
All(n=174)
* Male(n=83)
** Female(n=91)
**
Variable Subcategory Hazard Ratio P-value Hazard Ratio P-value Hazard Ratio P-value
MDM2 GG/GT 1.58(1.04–2.26) 0.0313 1.47(0.82–2.60) 0.1936 1.60(1.08–2.36) 0.0200
TT 1.00 1.00 1.00
MDM4 AG/GG 1.93(0.95–3.93) 0.0712 1.74(0.93–3.25) 0.0842 2.39(0.97–5.88) 0.0589
AA 1.00 1.00 1.00
p53 codon 72 PP 2.24(1.09–4.60) 0.0287 4.27(2.56–7.11) ,0.0001 1.33(0.59–3.01) 0.4864
PR/RR 1.00 1.00 1.00
Sex Female 1.39(0.94–2.04) 0.0970 - - --
Male 1.00 - -
Race Black 2.28(1.25–4.15) 0.0071 2.17(1.14–4.13) 0.0190 2.17(1.14–4.13) 0.0190
Others 0.99(0.62–1.56) 0.9523 0.99(0.64–1.53) 0.9447 0.99(0.64–1.53) 0.9447
White 1.00 1.00 1.00
Birth year 1.04(1.03–1.06) ,0.0001 1.04(1.03–1.06) ,0.0001 1.04(1.03–1.06) ,0.0001
*Adjusted for gender, race and birth year.
**Adjusted for race and birth year.
doi:10.1371/journal.pone.0010813.t003
Table 2. Univariable analysis of MDM2, MDM4, and p53 codon72 polymorphisms on age of tumor diagnosis using raw plus
imputed genotype data among carriers of a p53 germline mutation*.
Unadjusted Adjusted**
Variable Subcategory Hazard Ratio P-value Hazard Ratio P-value
MDM2 (G dominant, n=175) GG/GT=1,TT=0 1.45(0.96–2.19) 0.0764 1.40(0.93–2.10) 0.1067
MDM4 (G dominant,n=174) AG/GG=1,AA=0 1.43 (0.93–2.22) 0.1054 1.73(0.81–3.72) 0.1584
p53 codon 72(P rec, n=174) PP=1,PR/RR=0 2.22(1.27–3.89) 0.0052 2.03(1.06–3.89) 0.0327
Mutation type(n=175) Missense=1,Truncating=0 0.76(0.46–1.27) 0.2989
Missense-Cis72(n=71) P=1,R=0 1.41(0.83–2.41) 0.2026
Missense-Trans72(n=71) P=1,R=0 1.35(0.71–2.57) 0.3546
Truncating- Cis72(n=47) P=1,R=0 0.89(0.39–2.04) 0.7810
Truncating- Trans72(n=47) P=1,R=0 0.72(0.44–1.19) 0.2040
Sex(n=213) Female=1 1.56(1.15–2.11) 0.0039
Race(n=213) Black 1.16(0.65–2.05) 0.2081
Other 1.50(0.95–2.35)
Birth year(n=213) 1.04(1.03–1.05) ,0.0001
*Cox regression model.
**Adjusted for sex, race, and birth year in Cox regression model.
doi:10.1371/journal.pone.0010813.t002
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In this study, we evaluated whether specific genetic polymor-
phisms have any impact on risk of cancer in carriers of a p53
germline mutation. Among p53 carriers, cancer risk was
significantly higher in females than in males, but no difference
in cancer risk was found between missense and truncating
mutation groups. Our results demonstrate that MDM2 SNP309
and p53 codon 72 polymorphisms have strong genetic effects in
carriers of a p53 germline mutation. Cancer diagnosed in affected
carriers with MDM2 GG/GT was on average 9 years earlier than
that in affected carriers carrying the TT genotype. Although
MDM2 SNP309 was not a significant cancer risk factor via the log-
rank test or in univariable analysis, it was linked to a 1.58 times
greater likelihood of developing cancer than TT homozygosity
after adjusting for other confounders. A significant SNP309 effect
was observed in women but not in men. Patients with p53 72P
developed cancer 5 years earlier than individuals with RP/RR
genotypes, but the difference was not significant. In Cox regression
analysis, the p53 codon 72 PP genotype carried a significantly
higher risk of developing cancers. Our results indicate that a
multiplicative joint effect exists between the MDM2 and the p53
codon 72 polymorphism. However, no significant effects were
observed between MDM4 and cancer risk in germline mutation
carriers.
Bond et al. (2004) analyzed 88 affected mutation carriers and
found that the median age of tumor onset for those who carried
GG/GT (18 years) was 9.0 years earlier than that for those
carrying TT (27 years) (P=0.031) [10]. The present study is a
continuing follow-up cohort including some cancer cases studied
by Bond. However, our study is more accurate because it has more
samples and includes all p53 carriers, not just those who had
cancer. Bougeard et al. (2006) showed that, among 61 French
carriers of a germline p53 mutation (41 affected with cancer), the
mean age of tumor onset in those with MDM2 SNP309 GG/GT
(19.6 years) was significantly younger than in those with MDM2
TT (29.9 years) (P,0.05) [11]. Marcel et al. (2009) demonstrated
that, in a group of 32 cancer-affected Brazilian patients with LFS
or Li-Fraumeni2like syndrome and a germline p53 mutation, the
presence of a G allele was associated with a 12.5-year earlier
diagnosis (GG/GT 26.3 years versus TT 38.8; P=0.06) [12]. So
far all previous studies consistently show that MDM2 SNP309 can
accelerate tumor formation in carriers of a germline p53 mutation.
In the present study, comparison of mean age of tumor diagnosis
between affected carriers with different MDM2 SNP309 genotypes
revealed a significant difference, but the genotype did not
significantly affect the hazard for cancer development among all
carriers. When we adjusted for confounders, the MDM2 SNP309
effect became significant overall and we observed a 58% higher
cancer risk in the G allele carriers compared with TT
homozygotes. We also observed a higher risk from the MDM2
SNP309 genotypes in females, compared to males. The more
pronounced effect in females that we observed may relate to
biological regulation of MDM2 by estrogen. MDM2 SNP309 is
located in a region of the MDM2 promoter regulated by hormonal
signaling pathways. The G allele was demonstrated to enhance the
affinity of a co-transcriptional activator of multiple hormone
receptors, for example ER or Sp1. Bond et al. (2006) showed that
this polymorphism accelerated tumor formation in a gender-
specific fashion, and depended upon estrogen signaling [22]. This
finding suggested a genotype-dependent role for clinical manip-
ulation of hormone level in cancer prevention and treatment.
Interestingly, Bond et al. had a similar finding in 162 patients with
diffuse large B-cell lymphoma, where the G allele contributed to
earlier tumor onset only among females, but not among males
[22].
Bougeard et al. showed that the presence of the p53 72 R allele
accelerated tumor onset by 12.6 years in carriers of a germline p53
mutation (P,0.05) [11]. Marcel et al. reported that the R allele
reduced age at cancer diagnosis by almost 8 years in individuals
with LFS or Li-Fraumeni2like syndrome, although the difference
was not significant (P=0.22) [12]. Our findings that the PP
genotype increased risk after adjusting for cohort effects were in
conflict with those of the previous two studies, but were consistent
with the report of Martin et al. that the P72 allele was a risk factor
for breast cancer in 84 carriers with BRCA1 mutation [8]..
Dumont et al. reported that the p53 72R variant was 5- to 10-times
more likely to induce programmed cell death than the 72P variant,
and the authors suggested that the low apoptotic potential of the
72P variant might account for increased predisposition to cancer
development in carriers of the 72P variant [23].
In conclusion, our study confirms that the MDM2 SNP309 G
allele is associated with cancer risk in carriers of a p53 germline
mutation and that it accelerates tumor formation with a
pronounced effect in females. Our results also suggest that p53
codon 72 PP homozygosity is a risk factor for cancer. We found a
joint multiplicative effect of MDM2 SNP309 G allele and p53
codon 72 PP homozygosity. Our results provide insights that SNPs
further modify the risk for cancer development in individuals with
p53 mutations. In addition, given the high prevalence of p53
mutations in sporadic cancers, our findings may generalize to a
broader set of cancers.
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DOC)
Table S2 Primer sequences for genotyping assays.
Found at: doi:10.1371/journal.pone.0010813.s011 (0.03 MB
DOC)
Table S3 Univarible and multivariable analyses of MDM2,
MDM4, and p53 codon 72 polymorphisms on age of tumor
diagnosis using raw genotype data from carriers of a p53 germline
mutation.
Found at: doi:10.1371/journal.pone.0010813.s012 (0.04 MB
DOC)
Table S4 Distribution of allele frequencies by ethnicity.
Found at: doi:10.1371/journal.pone.0010813.s013 (0.03 MB
DOC)
Table S5 Genetic model selection using AIC in univariable
analysis of MDM2, MDM4, and p53 codon 72 polymorphisms on
age of tumor diagnosis using raw plus imputed genotype data
among carriers of a p53 germline mutation.
Found at: doi:10.1371/journal.pone.0010813.s014 (0.05 MB
DOC)
Table S6 Multivariable analysis of hazard ratio for MDM2,
MDM4, and p53 codon 72 polymorphisms on age of tumor
diagnosis among carriers of a p53 germline mutation, probands
excluded (n=126).
Found at: doi:10.1371/journal.pone.0010813.s015 (0.04 MB
DOC)
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